Navigation Links
Bayer/Schering-Plough/Shionogi's Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia
Date:4/17/2008

Superior Bacteriological Eradication and Activity Against Antibiotic-Resistant Pathogens Earn Avelox Gold Standard Status Through

2016, According to a New Report from Decision Resources

WALTHAM, Mass., April 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a therapy's overall clinical efficacy (defined as cure or improvement of symptoms) is the attribute that most influences primary care physicians' prescribing decisions for community-acquired pneumonia. Clinical data and expert opinion show that Bayer/Schering-Plough/Shionogi's Avelox (moxifloxacin) is similar in overall clinical efficacy to the market leader levofloxacin -- Johnson & Johnson's Levaquin, Sanofi-Aventis's Tavanic and Daiichi Sankyo's Cravit. However, Avelox's advantages in bacteriological efficacy, spectrum of activity, and activity against key antibiotic-resistant pathogens earn the agent gold standard status for community acquired pneumonia.

The new report entitled Community-Acquired Pneumonia: In a Crowded Generics-Dominated Market, Room for New Agents Still Exists finds that, through 2016, there are no therapies in development that will displace Avelox as the clinical gold standard for the treatment of community-acquired pneumonia. Although levofloxacin is superior to Avelox in the areas of safety and delivery -- offering a lower incidence of dermatological reactions and a five-day course of treatment -- Avelox outperforms levofloxacin on efficacy measures such as bacteriological eradication and activity against penicillin-resistant Streptococcus pneumoniae and Methicillin-resistant Staphylococcus aureus.

"Based on available data and expert opinion, we do not expect any therapy under development for community-acquired pneumonia to displace Avelox as the clinical gold standard for this indication through 2016," said John Lebbos, M.D. director at
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Astellas/GlaxoSmithKlines Vesicare Has Advantages Over Pfizers Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence
2. Cord Blood America Supports Trend From New York, California for States to Inform Parents of the Advantages of Umbilical Cord Blood Storage
3. Creative work has health advantages, Population Research Center study shows
4. Presentation at ISSN Highlights Soy Protein Advantages for Endurance Athletes
5. New Celebrity Introduces Students to Need, Advantages of Health Care Careers
6. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
7. MRI before surgery leads to better-adapted treatment for breast cancer
8. Obese women disadvantaged in both breast cancer treatment and diagnosis
9. Alcons PATANASE(R) Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms
10. Extra Drug Improves Rectal Cancer Treatment
11. Combining liver cancer treatments doubles survival rates, UVA researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... A pilot study by Massachusetts General Hospital (MGH) investigators ... unusual treatment for a serious medical problem use ... diarrhea caused by the Clostridium difficile ( ... published online in the journal Clinical Infectious Diseases ... fecal material from donors unrelated to patients was as ...
(Date:4/23/2014)... researchers say clinical trials for a new experimental ... very promising. Patients treated with CPX-351, a combination ... showing better responses than patients treated with the ... myeloid leukemia is an aggressive blood cancer with ... older patients," explained Jeffrey Lancet, M.D., senior member ...
(Date:4/23/2014)... A Michigan State University researcher is looking to give ... workout, and her latest research shows that a cyber ... the Games for Health Journal , is the ... still a better motivator during exercise, a software-generated partner ... that something that isn,t real can still motivate people ...
(Date:4/23/2014)... University researchers have developed a way to detect and ... tiny gold particles with tails of synthetic DNA., A ... biological engineering, used gold nanoparticles to target and bind ... RNA splice variants, which can indicate the presence and ... splice variants in a cell can be determined by ...
(Date:4/23/2014)... the gastro-intestinal tract has long been considered to be ... Sahlgrenska Academy have used refined microscopic techniques that indicate ... of the gastro-intestinal tract is only as large as ... The digestive tract, which passes from the mouth through ... length of about 5 meters in a normal adult, ...
Breaking Medicine News(10 mins):Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:Cyber buddy is better than 'no buddy' 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2
... Record Profitability and 12th Consecutive Year of Record ... ... $164 ... ST. LOUIS, Feb. 15 KV Pharmaceutical Company,(NYSE: KVa/KVb), a fully integrated ...
... One day doctors may recommend using high efficiency ... smoking cessation, and exercise to improve cardiovascular health, ... study, they found that using HEPA filters for ... of cardiovascular health in healthy, non-smoking elderly individuals. ...
... single prostate specific antigen (PSA) test at age 50 or ... 25 years later, (regardless of clinical significance) have now found ... prostate cancer. , The findings, published in the online ... men would benefit from intensive screening. , More men die ...
... Penn Bancshares Inc. (NASD:,NPBC) will replace Bradley Pharmaceuticals Inc. ... the close of trading on Thursday, February 21, 2008. ... on or about that date,pending final approvals., Standard ... relevant,updates on its website: http://www.standardandpoors.com ., National ...
... killer, but the recent findings of four Texas A&M University ... the dreaded disease. , Diabetics not only have high ... levels because they have trouble metabolizing glucose and fatty acids. ... acid aspects of diabetes separately because there was nothing linking ...
... Following the,company,s announcement of record unaudited revenues ... nutritional product manufacturer subsidiary InterACTIVE,Nutrition International, Inc., ... Board: NNTN) http://www.naturalnutritioninc.com ,announced today the ... common stock.,Each shareholder will receive one additional ...
Cached Medicine News:Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 2Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 3Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 4Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 5Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 6Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 7Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 8Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 9Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 10Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 11Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 12Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 13Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 14Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 15Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 16Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 17Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 18Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 19Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 20Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 21Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 22Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 23Health News:Using HEPA filters may improve cardiovascular health 2Health News:Early warning: PSA testing can predict advanced prostate cancer 2Health News:Standard & Poor's Announces Change to U.S. Index 2Health News:Research findings may lead to new ways to study and fight diabetes 2Health News:Research findings may lead to new ways to study and fight diabetes 3Health News:Natural Nutrition Announces Effectiveness of Forward Split of Common Stock Following 2007 Record Revenue Year 2
(Date:1/14/2014)... a manufacturer of ergonomically designed laboratory equipment for research, ... Japan to sell and service the Hitachi brand ... utilize its network of sales professionals throughout the United ... assistance in application use, product benefits and features, options and accessories, ...
(Date:1/14/2014)... VALHALLA, N.Y. , Jan. 14, 2014   Oligomerix, Inc. ... disease modifying therapeutics for Alzheimer,s disease (AD) and related ... headquarters to Valhalla, NY as ... additional laboratory space at New York Medical College. ...
(Date:1/14/2014)... Evidera , a leading provider of evidence-based solutions for ... Evaluation and Research (CDER), U.S. Food and Drug Administration, ... a patient-reported outcome (PRO) measure in drug development: ... for Measurement of Symptoms of Acute Bacterial Exacerbation of ...
Breaking Medicine Technology:NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
... PARIS--(BUSINESS WIRE)--Jun 11, 2007 - Regulatory News-Ipsen,(Paris:IPN) announced ... III study for its investigational 4-month formulation,of triptorelin ... triptorelin for a duration of 4 months in ... the second,administration as planned in the protocol. No ...
... 11, 2007 /PRNewswire/ -- NovaCardia, Inc.,today presented preliminary ... an adenosine A1 receptor antagonist in development for ... (CHF),that indicate a strong trend toward efficacy for ... a higher rate of,improvement in dyspnea, or shortness ...
Cached Medicine Technology:Phase III Clinical Trial with 4-Month Long-Acting Formulation of,Triptorelin: Ipsen Decides Not to Perform Further Administration 2Phase III Clinical Trial with 4-Month Long-Acting Formulation of,Triptorelin: Ipsen Decides Not to Perform Further Administration 3Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 2Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 3Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 4
... a surgical approach to glaucoma management that ... The ciliary body (which produces aqueous humour) ... anterior or posterior segment, through the endoscope ... easily and accurately identified utilizing endoscopy. This ...
... (ECP) is a surgical approach to glaucoma ... laser application. The ciliary body (which produces ... from the anterior or posterior segment, through ... tissues are easily and accurately identified utilizing ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek® ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
... a surgical approach to glaucoma management that ... The ciliary body (which produces aqueous humour) ... anterior or posterior segment, through the endoscope ... easily and accurately identified utilizing endoscopy. This ...
Medicine Products: